Latest Communications

18 January 2012
APR Applied Pharma Research s.a. (“APR”), Labtec GmbH (“Labtec”) and Norgine BV (“Norgine”) announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm™ Ondansetron Oral Dispersible Film (“ODF”), in Europe and selected non-European countries.

12 July 2011
MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners

13 June 2011
APR Applied Pharma Research s.a. and Labtec GmbH announce Ondansetron Oral Dispersible Film (“ODF”) is now available for licensing in Europe and selected non European countries, after having received marketing authorization in most countries of Europe.


Think Tank


For all those companies and Inventors who own innovative projects for which they wish to maintain an active role in exploiting them but do not have either development and marketing Know How or the required financial resources, we have created a great place where such projects can be shaped: we call it "Think Tank".


In the Think Tank area, APR is acting as a mix of strategic and financial investor able to provide a balanced mix of capital funding and development Know How channeled into a new company created ad hoc for that specific project and where the inventor can maintain an equity position enabling him to secure the upside potential.


We welcome your ideas and we will carefully listen to them: we will openly and professionally evaluate them all.





Search results